Key result
The pentavalent rotavirus vaccine (RV5) was projected to have an overall effectiveness of 82% to 89% against rotavirus gastroenteritis-related hospitalizations across six Asian countries.
Why the study?
Does oral pentavalent rotavirus vaccine (RV5) reduce rotavirus gastroenteritis-related hospitalizations and deaths in children <5 years of age in Asia?
Does oral pentavalent rotavirus vaccine (RV5) reduce rotavirus gastroenteritis-related hospitalizations and deaths in children <5 years of age in Asia?
Answers are grounded in this paper and cite their sources.
Mathematical modeling suggests that the oral pentavalent rotavirus vaccine could prevent 82-89% of rotavirus-related hospitalizations and substantially reduce deaths in Asian countries.
RotaTeq is an oral pentavalent rotavirus vaccine (RV5) that has shown high and consistent efficacy in preventing rotavirus gastroenteritis (RGE) in randomized clinical trials conducted mostly in industrialized countries. We projected the effectiveness of RV5 against RGE-related hospitalizations and deaths in 6 Asian countries by using a simple mathematical model. Model inputs included rotavirus surveillance data collected 2006-2007 in China, 2001-2002 in Hong Kong, 2005-2007 in India, 2005-2007 in South Korea, 2005-2007 in Taiwan, and 2001-2003 in Thailand; the numbers of rotavirus-related deaths in each country; and published rotavirus serotype-specific efficacy of RV5. The model projected an overall effectiveness in the region of 82% to 89% against RGE-related hospitalizations and a substantial reduction in RGE-related deaths, suggesting that RV5 could substantially reduce the burden of rotavirus disease in Asia.
No takes yet. Share an insight, caveat, or question.
Khoury et al. (2011) studied Rotavirus gastroenteritis. RotaTeq (oral pentavalent rotavirus vaccine, RV5) vs. No vaccination was evaluated on Projected effectiveness against RGE-related hospitalizations (82% to 89%). The pentavalent rotavirus vaccine (RV5) was projected to have an overall effectiveness of 82% to 89% against rotavirus gastroenteritis-related hospitalizations across six Asian countries.
Synapse has enriched 10 related papers. Consider them for comparative context: